JP2002515404A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002515404A5 JP2002515404A5 JP2000547993A JP2000547993A JP2002515404A5 JP 2002515404 A5 JP2002515404 A5 JP 2002515404A5 JP 2000547993 A JP2000547993 A JP 2000547993A JP 2000547993 A JP2000547993 A JP 2000547993A JP 2002515404 A5 JP2002515404 A5 JP 2002515404A5
- Authority
- JP
- Japan
- Prior art keywords
- prolactin
- cell
- treatment
- breast cancer
- prl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 description 29
- 102100029000 Prolactin receptor Human genes 0.000 description 15
- 108010002519 Prolactin Receptors Proteins 0.000 description 12
- 101000687438 Homo sapiens Prolactin Proteins 0.000 description 10
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 10
- 206010006187 Breast cancer Diseases 0.000 description 9
- 208000026310 Breast neoplasm Diseases 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- 238000002648 combination therapy Methods 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 7
- 239000000328 estrogen antagonist Substances 0.000 description 7
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 239000004471 Glycine Substances 0.000 description 6
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 6
- 206010060862 Prostate cancer Diseases 0.000 description 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 5
- 230000006907 apoptotic process Effects 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 229960001603 tamoxifen Drugs 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 239000004475 Arginine Substances 0.000 description 3
- 101001123448 Homo sapiens Prolactin receptor Proteins 0.000 description 3
- 108010057464 Prolactin Proteins 0.000 description 3
- 102000003946 Prolactin Human genes 0.000 description 3
- 230000002280 anti-androgenic effect Effects 0.000 description 3
- 239000000051 antiandrogen Substances 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940097325 prolactin Drugs 0.000 description 3
- 206010062767 Hypophysitis Diseases 0.000 description 2
- 229940046836 anti-estrogen Drugs 0.000 description 2
- 230000001833 anti-estrogenic effect Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 238000011284 combination treatment Methods 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000003635 pituitary gland Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 1
- 206010055113 Breast cancer metastatic Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 108010016076 Octreotide Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- TXUZVZSFRXZGTL-QPLCGJKRSA-N afimoxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=C(O)C=C1 TXUZVZSFRXZGTL-QPLCGJKRSA-N 0.000 description 1
- 230000001263 anti-prolactin effect Effects 0.000 description 1
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 1
- 229960002802 bromocriptine Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 229960002700 octreotide Drugs 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8512898P | 1998-05-12 | 1998-05-12 | |
| US24604199A | 1999-02-05 | 1999-02-05 | |
| US09/246,041 | 1999-02-05 | ||
| US60/085,128 | 1999-02-05 | ||
| PCT/US1999/010232 WO1999058142A1 (en) | 1998-05-12 | 1999-05-11 | Use of anti-prolactin agents to treat proliferative conditions |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010223963A Division JP2011079821A (ja) | 1998-05-12 | 2010-10-01 | 増殖性疾患を治療するための抗プロラクチン剤の使用 |
| JP2011149371A Division JP5453355B2 (ja) | 1998-05-12 | 2011-07-05 | 増殖性疾患を治療するための抗プロラクチン剤の使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002515404A JP2002515404A (ja) | 2002-05-28 |
| JP2002515404A5 true JP2002515404A5 (https=) | 2011-08-25 |
| JP5259896B2 JP5259896B2 (ja) | 2013-08-07 |
Family
ID=26772335
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000547993A Expired - Lifetime JP5259896B2 (ja) | 1998-05-12 | 1999-05-11 | 増殖性疾患を治療するための抗プロラクチン剤の使用 |
| JP2010223963A Withdrawn JP2011079821A (ja) | 1998-05-12 | 2010-10-01 | 増殖性疾患を治療するための抗プロラクチン剤の使用 |
| JP2011149371A Expired - Lifetime JP5453355B2 (ja) | 1998-05-12 | 2011-07-05 | 増殖性疾患を治療するための抗プロラクチン剤の使用 |
| JP2013127119A Withdrawn JP2013224309A (ja) | 1998-05-12 | 2013-06-18 | 増殖性疾患を治療するための抗プロラクチン剤の使用 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010223963A Withdrawn JP2011079821A (ja) | 1998-05-12 | 2010-10-01 | 増殖性疾患を治療するための抗プロラクチン剤の使用 |
| JP2011149371A Expired - Lifetime JP5453355B2 (ja) | 1998-05-12 | 2011-07-05 | 増殖性疾患を治療するための抗プロラクチン剤の使用 |
| JP2013127119A Withdrawn JP2013224309A (ja) | 1998-05-12 | 2013-06-18 | 増殖性疾患を治療するための抗プロラクチン剤の使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US7115556B2 (https=) |
| EP (2) | EP1079851B1 (https=) |
| JP (4) | JP5259896B2 (https=) |
| AT (1) | ATE366114T1 (https=) |
| AU (1) | AU3895299A (https=) |
| CA (1) | CA2328520C (https=) |
| DE (1) | DE69936451T2 (https=) |
| DK (1) | DK1079851T3 (https=) |
| ES (1) | ES2288777T3 (https=) |
| PT (1) | PT1079851E (https=) |
| WO (1) | WO1999058142A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1432064A (zh) | 2000-03-23 | 2003-07-23 | 格林维尔医院系统公司 | 双功能癌症治疗剂 |
| ES2346304T3 (es) * | 2002-06-12 | 2010-10-14 | L'oreal | Composicion cosmetica de cuidado y/o maquillaje estructurada con polimeros de silicona y agentes organogelificantes, en forma rigida. |
| WO2004054516A2 (en) * | 2002-12-13 | 2004-07-01 | The Ohio State University | Antagonists for human prolactin |
| JP5207590B2 (ja) | 2002-12-26 | 2013-06-12 | マウンテン ビュー ファーマシューティカルズ，インコーポレイテッド | 増強された生物学的能力を有するインターフェロン−βのポリマー結合体 |
| US8754031B2 (en) * | 2004-03-08 | 2014-06-17 | Oncolix, Inc. | Use of prolactin receptor antagonists in combination with an agent that inactivates the HER2/neu signaling pathway |
| US7507716B2 (en) * | 2005-07-06 | 2009-03-24 | Board Of Regents, The University Of Texas System | Method for treating pain with prolactin antagonists |
| WO2008028684A2 (en) * | 2006-09-08 | 2008-03-13 | Novo Nordisk A/S | Peptides with high affinity for the prolactin receptor |
| WO2008114077A1 (en) * | 2007-03-20 | 2008-09-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Constitutively active mutants of the prolactin receptor |
| WO2009003732A2 (en) * | 2007-07-05 | 2009-01-08 | Novo Nordisk A/S | Peptides with high affinity for the prolactin receptor |
| WO2009135056A2 (en) * | 2008-04-30 | 2009-11-05 | Monsanto Technology Llc | Recombinant dna vectors for expression of human prolactin antagonists |
| US8648046B2 (en) | 2009-02-26 | 2014-02-11 | Oncolix, Inc. | Compositions and methods for visualizing and eliminating cancer stem cells |
| EP2400979B1 (en) * | 2009-02-26 | 2015-05-20 | Oncolix, Inc. | Compositions and methods for visualizing and eliminating cancer stem cells |
| US8759289B2 (en) * | 2010-02-03 | 2014-06-24 | Orbis Health Solutions Llc | Method for sensitizing cancer stem cells to cancer therapy |
| TWI641620B (zh) | 2013-08-21 | 2018-11-21 | 再生元醫藥公司 | 抗－ｐｒｌｒ抗體及其用途 |
| US9545451B2 (en) | 2013-08-21 | 2017-01-17 | Regeneron Pharmaceuticals, Inc. | Anti-PRLR antibodies and methods for killing PRLR-expressing cells |
| EP3548514A1 (en) | 2016-11-29 | 2019-10-09 | Regeneron Pharmaceuticals, Inc. | Methods of treating prlr positive breast cancer |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4833516A (en) * | 1987-08-03 | 1989-05-23 | International Business Machines Corporation | High density memory cell structure having a vertical trench transistor self-aligned with a vertical trench capacitor and fabrication methods therefor |
| US5350836A (en) | 1989-10-12 | 1994-09-27 | Ohio University | Growth hormone antagonists |
| JP3417558B2 (ja) | 1991-05-10 | 2003-06-16 | ジェネンテク，インコーポレイテッド | 配位子作用薬および拮抗薬の選択 |
| US6429186B1 (en) | 1991-05-10 | 2002-08-06 | Genentech, Inc. | Ligand antagonists for treatment of breast cancer |
| US5590656A (en) * | 1992-09-15 | 1997-01-07 | The Ohio State University Research Foundation | Application of peptide/cell receptor kinetics utilizing radiolabeled somatostatin congeners in the in situ, in vivo detection and differentiation of neoplastic tissue |
| DE4231297A1 (de) | 1992-09-18 | 1994-03-24 | Basf Ag | Verfahren zur Herstellung von 3-(2'-Oxyethyl)-dihydro-2-(3H)furanonen |
| WO1994019004A1 (en) | 1993-02-19 | 1994-09-01 | Genentech, Inc. | Ligand antagonists for treatment of breast cancer |
| DK0754682T3 (da) * | 1994-04-06 | 2002-02-04 | Western Therapeutics Inst D | Aminostilbazolderivat og lægemiddel |
| DE19718721C2 (de) * | 1997-05-02 | 1999-10-07 | Siemens Ag | DRAM-Zellenanordnung und Verfahren zu deren Herstellung |
-
1999
- 1999-05-11 AT AT99921843T patent/ATE366114T1/de active
- 1999-05-11 AU AU38952/99A patent/AU3895299A/en not_active Abandoned
- 1999-05-11 ES ES99921843T patent/ES2288777T3/es not_active Expired - Lifetime
- 1999-05-11 JP JP2000547993A patent/JP5259896B2/ja not_active Expired - Lifetime
- 1999-05-11 WO PCT/US1999/010232 patent/WO1999058142A1/en not_active Ceased
- 1999-05-11 EP EP99921843A patent/EP1079851B1/en not_active Revoked
- 1999-05-11 PT PT99921843T patent/PT1079851E/pt unknown
- 1999-05-11 DE DE69936451T patent/DE69936451T2/de not_active Expired - Lifetime
- 1999-05-11 DK DK99921843T patent/DK1079851T3/da active
- 1999-05-11 CA CA2328520A patent/CA2328520C/en not_active Expired - Lifetime
- 1999-05-11 EP EP10010603A patent/EP2316467A1/en not_active Withdrawn
-
2002
- 2002-05-08 US US10/140,293 patent/US7115556B2/en not_active Expired - Lifetime
-
2006
- 2006-08-04 US US11/498,962 patent/US20070060520A1/en not_active Abandoned
-
2010
- 2010-10-01 JP JP2010223963A patent/JP2011079821A/ja not_active Withdrawn
-
2011
- 2011-07-05 JP JP2011149371A patent/JP5453355B2/ja not_active Expired - Lifetime
-
2013
- 2013-06-18 JP JP2013127119A patent/JP2013224309A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002515404A5 (https=) | ||
| Öberg et al. | Somatostatin analogues in acromegaly and gastroenteropancreatic neuroendocrine tumours: past, present and future | |
| Stahnke et al. | Long-term follow-up of children with craniopharyngioma | |
| Cabello-Verrugio et al. | Angiotensin II: role in skeletal muscle atrophy | |
| Gola et al. | Resistance to somatostatin analogs in acromegaly: an evolving concept? | |
| Vance | Treatment of patients with a pituitary adenoma: one clinican's experience | |
| Bracci | Antiandrogens in the treatment of prostatic cancer | |
| Stewart | Pegvisomant: an advance in clinical efficacy in acromegaly | |
| Pawlikowski et al. | Perspectives of new potential therapeutic applications of somatostatin analogs | |
| Farnsworth et al. | Prolactin and prostate cancer | |
| JP6743001B2 (ja) | シス−クロミフェンを用いたアンドロゲン除去療法によって生じるホットフラッシュ及び骨量減少の治療 | |
| Parkinson et al. | Pegvisomant in the treatment of acromegaly | |
| Shomali et al. | Medical therapy for gonadotroph and thyrotroph tumors | |
| Donangelo et al. | Treatment of acromegaly: future | |
| MX2008015666A (es) | Combinacion de analogos de somatostatina con un agonista de dopamina o un antagonista del receptor de hormona de crecimiento. | |
| Cannavò et al. | Results of a two-year treatment with slow release lanreotide in acromegaly | |
| Mosdell et al. | Emerging indications for octreotide therapy, Part 1 | |
| Kasperlik-Zaluska et al. | ACTH responses to somatostatin, valproic acid and dexamethasone in Nelson's syndrome | |
| Chang et al. | Serial follow-up of presurgical treatment using pasireotide long-acting release with or without octreotide long-acting release for naïve active acromegaly | |
| Roy et al. | Effects of teriparatide treatment on bone mineral density in patients with osteoporosis: a short-term dose-response study | |
| Schneyer et al. | Inhibition of cyclocytidine-induced enlargement of parotid and heart by propranolol or sympathectomy | |
| Parkinson et al. | The place of pegvisomant in the management of acromegaly | |
| Gradišer et al. | Decrease in growth hormone and insulin-like growth factor (IGF)-1 release and amelioration of acromegaly features after Rosiglitazone treatment of type 2 diabetes mellitus in a patient with acromegaly | |
| Rossitch Jr et al. | The deafferentation syndrome in the rat: effects of intraventricular neurotensin and cholecystokinin | |
| Meas et al. | An unusual somatotropin and thyreotropin secreting pituitary adenoma efficiently controlled by Octreotide and Pegvisomant |